HER2-positive breast cancer

Prof. Martine Piccart grew up in a house where medicine was part of the air. Her father, a gynecologist, treated patients at home. “I admired him deeply,” she says. “He helped people. I saw that up close. It left a…

It’s long been clear that, in most patients with metastatic HER-positive breast cancer, adding effective HER2 blockade to cytotoxics can result in very prolonged responses. Janet Fricker reports on the prospective trials building evidence on whether – and in whom…